Phase 3
Completed N=488
Child and Adolescent Anxiety Disorders (CAMS)
Anxiety · Social Phobia
Source: ClinicalTrials.gov NCT00052078 ↗
Enrolled (actual)
488
Serious AEs
0.6%
Results posted
Apr 2017
Primary outcomePrimary: Clinical Global Impression - Improvement Scale — 54.9; 59.7; 80.7; 23.7 percentage of participants
◆ Published Evidence
Highly cited
1,443citations · ~80 / year
Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety.
Summary
This randomized, controlled trial compared the efficacy of the medication sertraline (Zoloft®), cognitive-behavioral therapy, the combination of these treatments, and placebo for youth with anxiety disorders.
Linked Publications (5)
-
Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety.
-
Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS.
-
Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods.
-
Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial.
-
24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinical Global Impression - Improvement Scale |
54.9; 59.7; 80.7; 23.7 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for separation anxiety disorder, social phobia, or generalized anxiety disorder
Exclusion Criteria
- Major neurological disorder or medical illness that would interfere with participation in the study
Data sourced from ClinicalTrials.gov (NCT00052078) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.